Response and remission rates during 24 weeks of mood-stabilizing treatment for bipolar depression depending on early non-response
| Autor: | Louisa G. Sylvia, Michael J. Ostacher, Mauricio Tohen, James H. Kocsis, Terence A. Ketter, Ole Köhler-Forsberg, Melvin G. McInnis, Edward S. Friedman, Michael E. Thase, Richard C. Shelton, Andrew A. Nierenberg, Kirstine H. Sloth, Joseph R. Calabrese, Charles L. Bowden, Susan L. McElroy, Dan V. Iosifescu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
Adult medicine.medical_specialty Bipolar Disorder Lithium (medication) Bipolar depression Lithium Antidepressant treatment Quetiapine Fumarate Double-Blind Method Mood-stabilizing Internal medicine medicine Humans Biological Psychiatry Depression (differential diagnoses) business.industry Quetiapine Response Quetiapine Fumarate/therapeutic use Psychiatry and Mental health Affect Mood Treatment Outcome Lithium/therapeutic use Bipolar Disorder/chemically induced Early non-response Female business Antipsychotic Agents/therapeutic use Antipsychotic Agents medicine.drug |
| Zdroj: | Köhler-Forsberg, O, Sloth, K H, Sylvia, L G, Thase, M, Calabrese, J R, Tohen, M, Bowden, C L, McInnis, M, Kocsis, J H, Friedman, E S, Ketter, T A, McElroy, S L, Shelton, R C, Iosifescu, D V, Ostacher, M J & Nierenberg, A A 2021, ' Response and remission rates during 24 weeks of mood-stabilizing treatment for bipolar depression depending on early non-response ', Psychiatry Research, vol. 305, 114194 . https://doi.org/10.1016/j.psychres.2021.114194 |
| Popis: | Background We aimed to study the probability of bipolar depression response at 24 weeks given initial non-response. Methods We combined two multi-site, 24-week trials including similar populations following the same evidence-based guidelines randomizing patients to lithium or quetiapine. Additional mood-stabilizing treatment was possible if clinically indicated. We report cumulative proportions of response (>50% improvement in MADRS) and remission (MADRS Results We included 592 participants with bipolar depression (mean 39 years, 59% female, mean MADRS 25). Among 393 (66%) participants without response after 2 weeks, 46% responded by 24 weeks; for 291 (49%) without response at 4 weeks, 40% responded and 33% remitted by 24 weeks; for 222 (38%) without a response at 6 weeks, 36% responded and 29% remitted by 24 weeks; for 185 (31%) without a response at 8 weeks, 29% responded and 24% remitted by 24 weeks. Rates were similar for participants who had started an additional mood-stabilizing drug during the first 6 or 8 weeks. Conclusions Among patients with bipolar depression and non-response after 6 weeks treatment, representing an adequate bipolar depression trial, only one-third responded by 24 weeks. These results highlight the need for better treatment alternatives for non-responders to evidence-based treatments for bipolar depression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|